Organization · Accelerator
BaseLaunch
BaseLaunch is a biotech accelerator and incubator in Basel, Switzerland, focused on launching and growing biotech ventures in therapeutics, diagnostics, and vaccines.
Overview
What BaseLaunch does
What BaseLaunch is
BaseLaunch is a biotech accelerator and incubator in Basel, Switzerland, focused on launching and growing biotech ventures in therapeutics, diagnostics, and vaccines.
How it participates in the startup ecosystem
The current public profile supports funder and program host capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Accelerator
- Structured capabilities
- Funder · Program host
- Last reviewed
- April 11, 2026
What Accelerator means
An accelerator is a structured, short-term program designed to speed up a startup's progress toward product-market fit, traction, fundraising, or scale.
Open the glossary entryOfficial channels
Find BaseLaunch elsewhere
Open the official website or a supported primary organization account.
Capability profile
BaseLaunch as a funder
Investment thesis
BaseLaunch partners with scientists and entrepreneurs to launch and grow biotech ventures that develop therapeutics.
Focus narrative
BaseLaunch invests in biotech companies developing therapeutics across various sectors, including oncology, CNS, immunology, inflammation, metabolic, cardiovascular, and antivirals. The organization supports projects at any stage from pre-seed to seed, particularly those with breakthrough innovations.
Value beyond capital
BaseLaunch offers funding of up to CHF 500,000 to support biotech ventures and encourages early engagement with potential applicants to improve their chances of receiving funding.
Terms and economics
- Typical check
- $0–$500,000
Focus and fit
- Stages
- Pre-seed · Seed · Accelerator
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 30
Portfolio context
BaseLaunch has a diverse portfolio of biotech companies, including: Alentis Therapeutics: Raised $366M for anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies targeting cancer and fibrosis. Anaveon: Raised $155M for cytokine-based cancer therapies. Cimeio Therapeutics: Raised $50M for cell-shielding and immunotherapies for hematologic disorders. Engimmune: Raised $16M for targeted T cell receptor therapies for solid tumors. FimmCyte: Focuses on therapies for endometriosis and chronic fibrotic diseases.
Capability profile
BaseLaunch as a program host
Program thesis
BaseLaunch partners with scientists and entrepreneurs to launch and grow biotech ventures that develop therapeutics.
Focus narrative
BaseLaunch invests in biotech companies developing therapeutics across various sectors, including oncology, CNS, immunology, inflammation, metabolic, cardiovascular, and antivirals. The organization supports projects at any stage from pre-seed to seed, particularly those with breakthrough innovations.
Value and support
BaseLaunch offers funding of up to CHF 500,000 to support biotech ventures and encourages early engagement with potential applicants to improve their chances of receiving funding.
Additional public guidance
Q: What is the funding amount available? A: BaseLaunch offers funding of up to CHF 500,000. Q: When is the next application deadline? A: The next application deadline is May 7, 2026.
Terms and economics
- Indicative investment
- $500,000
Availability
- Application state
- Accepting
- Next deadline
- May 7, 2026
Focus and fit
- Stages
- Pre-seed · Seed
- Regions
- Europe
Alumni and track record
Alumni context
BaseLaunch has a diverse portfolio of biotech companies, including Alentis Therapeutics, which raised $366M for anti-Claudin-1 antibody-drug conjugates; Anaveon, which raised $155M for cytokine-based cancer therapies; Cimeio Therapeutics, which raised $50M for immunotherapies; Engimmune, which raised $16M for targeted T cell receptor therapies; and FimmCyte, focusing on therapies for endometriosis.
Common questions
What to know about BaseLaunch
Upseed classifies BaseLaunch under the Accelerator organization type. Its current public profile includes funder and program host capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 11, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.